Kuwana M, Medsger T A, Wright T M
Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.
Clin Immunol Immunopathol. 1995 Sep;76(3 Pt 1):266-78. doi: 10.1006/clin.1995.1125.
Five recombinant fusion proteins with overlapping amino acid sequences encompassing the entire DNA topoisomerase I (topo I) molecule were generated, purified, and used as antigens for an enzyme-linked immunosorbent assay (ELISA). IgG, IgA, IgM, and "total" (total of IgG, IgA, and IgM isotypes) anti-topo I antibodies were measured using a mixture of these five fusion proteins in 73 systemic sclerosis (SSc) sera positive for anti-topo I antibody by double immunodiffusion (DID) and 184 control sera negative for anti-topo I antibody by DID. Fragment-specific anti-topo I antibodies were also measured by ELISA using each topo I recombinant protein as antigen. IgG, IgA, IgM, and total anti-topo I antibodies were detected in 67 (92%), 56 (77%), 16 (22%), and 70 (96%) of 73 SSc sera positive for anti-topo I antibody by DID, respectively. The specificity of the total anti-topo I ELISA was 99% when compared with DID. The total anti-topo I ELISA levels were strongly correlated with DID titers (r = 0.907, P < 0.0001). Three sera which recognized a conformational epitope on native topo I or had predominantly IgM anti-topo I antibody showed a false-negative result with the total anti-topo I ELISA. Three SSc sera negative for anti-topo I antibody by DID were positive by the total anti-topo I ELISA, and two were confirmed to recognize the N-terminus of topo I. IgG and IgA antibody levels to the N-terminal and central portion of topo I were correlated with each other, but those to the C-terminus were not. These findings indicate that the ELISA using recombinant fusion proteins is a highly sensitive and specific alternative to conventional DID for the detection of anti-topo I antibody.
我们制备、纯化了五种重组融合蛋白,其氨基酸序列相互重叠,覆盖了整个DNA拓扑异构酶I(拓扑异构酶I)分子,并将其用作酶联免疫吸附测定(ELISA)的抗原。使用这五种融合蛋白的混合物,对73份经双向免疫扩散(DID)检测抗拓扑异构酶I抗体呈阳性的系统性硬化症(SSc)血清和184份经DID检测抗拓扑异构酶I抗体呈阴性的对照血清中的IgG、IgA、IgM和“总”(IgG、IgA和IgM同种型的总和)抗拓扑异构酶I抗体进行了检测。还以每种拓扑异构酶I重组蛋白为抗原,通过ELISA检测片段特异性抗拓扑异构酶I抗体。在73份经DID检测抗拓扑异构酶I抗体呈阳性的SSc血清中,分别有67份(92%)、56份(77%)、16份(22%)和70份(96%)检测到IgG、IgA、IgM和总抗拓扑异构酶I抗体。与DID相比,总抗拓扑异构酶I ELISA的特异性为99%。总抗拓扑异构酶I ELISA水平与DID滴度高度相关(r = 0.907,P < 0.0001)。三份识别天然拓扑异构酶I上构象表位或主要含有IgM抗拓扑异构酶I抗体的血清,在总抗拓扑异构酶I ELISA检测中呈假阴性结果。三份经DID检测抗拓扑异构酶I抗体呈阴性的SSc血清,在总抗拓扑异构酶I ELISA检测中呈阳性,其中两份被证实识别拓扑异构酶I的N端。针对拓扑异构酶I N端和中部的IgG和IgA抗体水平相互相关,但针对C端的抗体水平则不然。这些发现表明,使用重组融合蛋白的ELISA在检测抗拓扑异构酶I抗体方面,是一种比传统DID更具高敏感性和特异性的方法。